Health Care · Services-Commercial Physical & Biological Research

IQV IQVIA SEC Filings & Insider Trading Activity 2026

company
CIK 1478242141 filings
S&P 500

IQV at a glance

IQVIA (IQV, SEC CIK 1478242) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), IQVIA (IQV) reported revenue of $16.3 billion (up 5.9% from FY2024) and net income of $1.4 billion. Diluted EPS was $7.84.
  • As of September 30, 2026, 43 institutional investment managers tracked by SignalX reported holding IQVIA (IQV) shares worth $18.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Sherbet Eric on November 9, 2026 of 4,446 shares at $278.83 per share.
  • In the last 90 days, IQV insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.9M) on Form 4, a net sale of $1.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$16.3B
+5.9% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$1.9M
13F holders
43 funds
$18.0B · −3 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Global clinical development and commercial solutions services for biopharmaceutical industry
  • Emphasis on risks from client consolidation reducing service volumes and revenue loss post-mergers in clients’ industries
  • Increased focus on managing complex international regulatory, economic, and political risks impacting multi-country clinical trials
  • Workforce strategy: Leveraging global hiring in lower-cost countries to improve efficiency amid competition and wage inflation pressures
  • Noteworthy sustainability risk disclosure: Evolving global regulatory and stakeholder demands on sustainability could raise costs and reputational risks

Risk Factors

  • Regulatory risk: Compliance with HIPAA and EU GDPR, with potential fines and penalties under US Dept. of Health and Human Services and EU authorities
  • Geopolitical risk: Increased cyberattack threat from state-sponsored actors causing data compromise and operational disruption in global IT systems
  • Supply chain risk: Dependence on third-party suppliers for clinical trial materials and data; supplier restrictions or failures may materially harm operations
  • Competitive risk: Risk of lost or delayed large contracts due to clients shifting business to competitors or internal resources in biopharma services
  • Financial risk: Senior Secured Credit Facilities and note indentures restrict financing and operational flexibility, potentially limiting growth initiatives

Management Discussion & Analysis

  • Revenue $16,310M in 2025, up 5.9% (+$905M) YoY; Technology & Analytics Solutions +7.6% ($466M), Research & Development Solutions +4.3% ($369M), Contract Sales & Medical Solutions +9.7% ($70M)
  • Operating profit $2,182M in 2025, down 0.9% from $2,202M in 2024; segment profit: Technology & Analytics $1,595M (+4.8%), R&D $1,873M (-3.9%), Contract Sales $48M (+2.1%)
  • Best performing segment: Technology & Analytics Solutions revenue growth 7.6%, profit +4.8%; Worst performing segment: Research & Development Solutions profit decline by 3.9% despite revenue growth
  • Operating cash flow $2,654M; $1,714M net cash invested in acquisitions; cash and equivalents $1,980M (+$278M); $1,769M remaining stock repurchase authorization; total debt $15,800M, compliant with covenants
  • Management guidance: ongoing restructuring to streamline operations; expected continued integration of segments beginning 2026; risks from macroeconomic uncertainty, client cautiousness, and foreign currency fluctuations

AI summary of the IQV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from 2025 Form 10-K risk factors
  • Carried-forward business risks remain the principal disclosed exposures
  • No newly added regulatory, legal, or compliance risk identified
  • No newly disclosed operational, competitive, market, or financial risk identified

Management Discussion & Analysis

  • Revenue $4,428M, up 8.0% YoY from $4,100M
  • Effective tax rate 19.7% vs 18.6% YoY
  • Research & Development Solutions strongest segment: revenue $2,639M, up 8.7% YoY
  • Cash $2,249M vs $1,980M at December 31, 2025; operating cash flow $2,001M vs $1,919M
  • Backlog $32.6B vs $34.0B, including $2.1B reduction from refined assessment criteria

AI summary of the IQV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $4,428M, up 8.0%, with Adjusted EPS $3.34, up 11.3%, signaling strong operating momentum
  • R&DS net new bookings $3.2B, up 15%, and $32.6B backlog support revenue visibility, including $9.4B expected within twelve months

Item 2.02: Results of Operations and Financial Condition

  • IQVIA announced third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Full financial results available in Exhibit 99.1 and the company’s website
Filed Sep 23, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $2.0B senior notes issued at 6.375% interest, maturing March 15, 2034
  • Proceeds refinance 5.000% notes due 2026 and repay revolving credit borrowings

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a newly created direct financial obligation tied to the disclosed material agreement
  • Investors should review Item 1.01 for obligation size, payment terms, maturity and potential balance-sheet impact
Filed Sep 9, 2026Full analysis →

Item 8.01: Other Events

  • IQVIA subsidiary plans $2.0B senior-notes issuance due 2034 at 6.375% annual interest
  • Proceeds earmarked to redeem $2026 notes, reduce revolving-credit debt, and cover offering expenses

Item EX-99.1: Item EX-99.1

  • $2.0B senior notes offering due 2034, subject to market and customary closing conditions
  • Proceeds earmarked to redeem 5.000% notes due 2026 and repay revolving credit facility borrowings

Item EX-99.2: Item EX-99.2

  • $2.0B senior notes issuance due 2034, extending debt maturity to March 15, 2034
  • 6.375% annual coupon, semiannual interest payments beginning March 15, 2027

AI summaries of IQV 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IQV

Don't miss the next IQV filing

  • Alerts as it files. A push when IQV files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IQV, by share count.
  • Ask anything. An AI agent that reads every IQV filing and answers with sources.

IQV alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Sherbet EricMNov 9, 2026$131.82
Sherbet EricSellNov 9, 2026$278.83
Sherbet EricDNov 9, 2026$278.74
Sherbet EricMNov 9, 2026$131.82
Wims Morris LeslieANov 5, 2026$264.88
GOGGINS COLLEEN AANov 5, 2026$264.88
Fasano JimANov 5, 2026$264.88
DANHAKL JOHN GANov 5, 2026$264.88

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$15.0B$15.4B$16.3B
Operating Income$2.0B$2.2B$2.2B
Net Income-$1.4B$1.4B
Op. Margin13.2%14.3%13.4%
Net Margin-8.9%8.3%
Balance Sheet
Total Assets$26.7B$26.9B$29.9B
Equity$6.1B$6.1B$6.5B
ROE-22.6%20.9%
Per Share
EPS$7.29$7.49$7.84
Cash Flow
Operating CF$2.1B$2.7B$2.7B

Source: XBRL data in IQVIA (IQV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IQV share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IQV shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202643$18.04B
Q2 202646$13.48B
Q1 202644$11.73B
Q4 202543$15.80B
Q3 202540$13.85B
Q2 202539$10.79B
Q1 202537$9.19B
Q4 202434$8.68B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 326 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IQV filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
8-KOct 27, 2026Analysis-
10-QOct 27, 2026Analysis
8-KSep 23, 2026Analysis-
8-KSep 9, 2026Analysis-
4Sep 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Jul 31, 2026--
4Jul 31, 2026--
4Jul 31, 2026--
8-KJul 28, 2026Analysis-
10-QJul 28, 2026Analysis
4Jul 16, 2026--
4Jul 16, 2026--
4Jul 16, 2026--
4Jul 16, 2026--
8-KJun 11, 2026Analysis-
8-KJun 4, 2026Analysis
8-KJun 3, 2026Analysis
4May 11, 2026-

Related Health Care companies

All Health Care →

IQV SEC filings: frequently asked questions

Are IQV insiders buying or selling?

In the last 90 days, IQVIA (IQV) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.9 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IQV stock?

As of September 30, 2026, the largest IQVIA (IQV) holders among the 13F filers tracked by SignalX were BlackRock ($3.9 billion), Vanguard Capital Management LLC ($2.9 billion), State Street Corp ($2.0 billion), Vanguard Portfolio Management LLC ($2.0 billion), JPMorgan Chase & Co ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IQV's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), IQVIA (IQV) reported revenue of $16.3 billion (up 5.9% from FY2024) and net income of $1.4 billion. Diluted EPS was $7.84. The figures come from the XBRL data in the 10-K.

What are the main risks in IQV's latest 10-K?

In the 10-K filed February 17, 2026, IQVIA (IQV) flagged: Regulatory risk: Compliance with HIPAA and EU GDPR, with potential fines and penalties under US Dept. of Health and Human Services and EU authorities. Geopolitical risk: Increased cyberattack threat from state-sponsored actors causing data compromise and operational disruption in global IT systems. (AI summary of the Risk Factors section.)

What did IQV report in its latest 8-K?

IQVIA (IQV) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $4,428M, up 8.0%, with Adjusted EPS $3.34, up 11.3%, signaling strong operating momentum.

What are the latest IQV SEC filings?

IQVIA (IQV) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 27, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on November 12, 2026.

What is IQV's SEC CIK number?

IQVIA (IQV)'s SEC Central Index Key (CIK) is 1478242. EDGAR lists every IQV filing under that number.

Ask anything about IQV

The research agent reads IQV's filings, financials, insider trades and 13F holders, then answers with sources.